Litcius/Paper detail

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Ilary Ruscito, Filippo Bellati, Isabelle Ray‐Coquard, Mansoor Raza Mirza, Andreas du Bois, Maria Luisa Gasparri, Flavia Costanzi, Maria Paola De Marco, Marianna Nuti, Donatella Caserta, Sandro Pignata, Oliver Dorigo, Jalid Sehouli, Elena Ioana Braicu

2020Cancer Treatment Reviews56 citationsDOI

Topics & Concepts

MedicineInternal medicineOncologyBevacizumabOvarian cancerCancerRandomized controlled trialPARP inhibitorAnemiaChemotherapyGastroenterologyPoly ADP ribose polymerasePolymeraseBiochemistryChemistryGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials | Litcius